Select your Market
Financial results for Q1 2026
| Q1 2026 | Change (in %, compared to Q1 2025) | Organic change (in %, compared to Q1 2025) |
|---|---|---|---|
Group net sales | 5.1 | –2.8 | 2.9 |
EBITDA pre | 1.5 | –0.3 | 5.3 |
Life Science sales | 2.3 | 2.2 | 8.3 |
Healthcare sales | 2.1 | –3.0 | -3.4 |
Electronics sales | 0.8 | –13.9 | 4.2 |
Our first-quarter performance underlines the strength of the company’s diversified portfolio and its clear focus on complementary science and technology businesses. We upgrade our full-year 2026 financial guidance. At the same time, we sharpen the strategic direction of the company for the long-term.
Detailed information about the development of our business in the first quarter of 2026.
Downloads for the Media
Press Releases
The Group generated moderate organic sales growth and sustained profitability.
2026/05/13
Our Q2 2026 results will be published on August 6, 2026, at 7 a.m. (CEST). Our conference call for the media will take place at 09:30 a.m. (CEST), and the conference call for analysts at 2 p.m. (CEST)
Our Q3 2026 results will be published on November 12, 2026, at 7 a.m. (CEST). Our conference call for the media will take place at 09:30 a.m. (CEST), and the conference call for analysts at 2 p.m. (CEST)
